Butyrate-modified liposomes target the delivery of itaconic acid to modulate the Th17/Treg cell balance through epigenetic reprogramming, improving primary biliary cholangitis
Primary biliary cholangitis (PBC) is a chronic autoimmune disease. This study aims to design itaconic acid (IA)-loaded butyrate (Bu)-modified lipid nanoparticles (LNP-Bu@IA) for targeted delivery of IA, modulate the Th17/Treg cell balance through metabolic and epigenetic reprogramming, improve PBC, and provide a novel strategy for its treatment